- Home
- AIN vs ACAD Comparison
AIN vs ACAD Comparison
Compare AIN & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIN
- ACAD
- Stock Information
- Founded
- AIN 1895
- ACAD 1993
- Country
- AIN United States
- ACAD United States
- Employees
- AIN N/A
- ACAD N/A
- Industry
- AIN Textiles
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- AIN Consumer Discretionary
- ACAD Health Care
- Exchange
- AIN Nasdaq
- ACAD Nasdaq
- Market Cap
- AIN 2.5B
- ACAD 2.8B
- IPO Year
- AIN 1987
- ACAD 2004
- Fundamental
- Price
- AIN $63.42
- ACAD $14.73
- Analyst Decision
- AIN Buy
- ACAD Buy
- Analyst Count
- AIN 5
- ACAD 16
- Target Price
- AIN $80.40
- ACAD $23.93
- AVG Volume (30 Days)
- AIN 318.6K
- ACAD 1.8M
- Earning Date
- AIN 04-28-2025
- ACAD 05-07-2025
- Dividend Yield
- AIN 1.67%
- ACAD N/A
- EPS Growth
- AIN N/A
- ACAD N/A
- EPS
- AIN 2.80
- ACAD 1.36
- Revenue
- AIN $1,230,615,000.00
- ACAD $957,797,000.00
- Revenue This Year
- AIN $1.49
- ACAD $13.07
- Revenue Next Year
- AIN $4.48
- ACAD $9.88
- P/E Ratio
- AIN $22.65
- ACAD $10.83
- Revenue Growth
- AIN 7.21
- ACAD 31.85
- 52 Week Low
- AIN $57.71
- ACAD $13.40
- 52 Week High
- AIN $95.47
- ACAD $20.68
- Technical
- Relative Strength Index (RSI)
- AIN 38.10
- ACAD 38.07
- Support Level
- AIN $62.77
- ACAD $14.34
- Resistance Level
- AIN $66.30
- ACAD $15.18
- Average True Range (ATR)
- AIN 3.10
- ACAD 0.80
- MACD
- AIN 0.10
- ACAD -0.02
- Stochastic Oscillator
- AIN 41.29
- ACAD 38.22
About AIN Albany International Corporation
Albany International Corp is principally engaged in processing textiles and materials. The company consists of two business segments, the machine clothing segment, which produces and provides custom-designed fabrics and belts for the production in the paper, nonwovens, and other process industries; and the Albany engineered composites segment, which offers engineered composite parts for the aerospace and defensive industries. The machine clothing segment contributes to the majority of the company's total revenue. The company has an operation and generates revenue from the United States, Switzerland, Brazil, China, Mexico, France, and other areas.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.